NCT05448625View on ClinicalTrials.gov

Genoss DES in Patients With a High Risk of Ischemic Events (GENTLE Registry)

RecruitingOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

May 26, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2026

Conditions
Drug-eluting StentCoronary Artery Disease
Interventions
DEVICE

Genoss DES

The Genoss DES (Genoss, Korea) L-605 cobalt chromium (CoCr) platform with a strut thickness of 70 µm Sirolimus drug with concentration of 1.15µg/mm2 Abluminal biodegradable PLA and PLGA polymers.

Trial Locations (1)

16995

RECRUITING

Yongin Severance Hospital, Yongin

All Listed Sponsors
collaborator

Severance Hospital

OTHER

collaborator

Genoss Co., Ltd.

INDUSTRY

lead

Yonsei University

OTHER